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Abstract: Active targeting is a valuable and promising approach with which to enhance the ther-
apeutic efficacy of nanodelivery systems, and the development of tumor-targeted nanoparticles
has therefore attracted much research attention. In this field, the research carried out in Italian
Pharmaceutical Technology academic groups has been focused on the development of actively
targeted nanosystems using a multidisciplinary approach. To highlight these efforts, this review
reports a thorough description of the last 10 years of Italian research results on the development of
actively targeted nanoparticles to direct drugs towards different receptors that are overexpressed
on cancer cells or in the tumor microenvironment. In particular, the review discusses polymeric
nanocarriers, liposomes, lipoplexes, niosomes, solid lipid nanoparticles, squalene nanoassemblies
and nanobubbles. For each nanocarrier, the main ligands, conjugation strategies and target receptors
are described. The literature indicates that polymeric nanoparticles and liposomes stand out as key
tools for improving specific drug delivery to the site of action. In addition, solid lipid nanoparticles,
squalene nanoparticles and nanobubbles have also been successfully proposed. Taken together,
these strategies all offer many platforms for the design of nanocarriers that are suitable for future
clinical translation.
Keywords: cancer therapy; active targeting; ligand; receptor; liposomes; solid lipid nanoparticles;
polymeric nanocarriers; nanobubbles
1. Introduction
Cancer is a leading cause of death worldwide and has a significant impact on society
in terms of productivity loss and poor health-related quality of life. Current strategies
for cancer treatment are mostly based on conventional chemotherapy, which is highly
non-specific in targeting drugs to the cancer and can therefore affect both cancerous and
normal cells [1]. To overcome these drawbacks, scientists have made intensive efforts
for several decades to maximize the killing effect of chemotherapeutic agents on cancer
cells and minimize the adverse effects on healthy tissues by achieving better therapy
targeting/localization [2].
The application of nanomedicine in cancer therapy, with the aim of striking and selec-
tively destroying the targets, has aroused significant interest both in the academic and the
industrial fields [3,4]. Cancer nanomedicine is a constantly progressing science that is based
on innovative physicochemical concepts and materials, and has been exploited to design
nanotherapeutics, i.e., submicron novel drug-carrier systems, defined as nanocarriers, that
may be able to overcome the many limitations of conventional drugs, such as poor water
solubility, unfair oral bioavailability, non-specific biodistribution and a lack of targeting
ability [5–8]. Nanomedicine has gained considerable interest due to its ability to overcome
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the challenges of tumor therapy, such as metastasis and multi-drug resistant or recurrent
tumors [9].
Moreover, most biopharmaceutical molecules, such as nucleic acids and proteins,
have poor cell-membrane permeability and are easily degraded in vivo, and this obviously
prevents their direct use. Consequently, the clinical use of this kind of product in therapy
should be improved with vehicles that can protect them from degradation and ensure
selective release to the target [2]. The recently developed mRNA-based vaccines to prevent
the SARS-CoV-2 infection, vaccines which are composed of lipid nanoparticles (NPs), are
an important recent therapeutic application of a nanomedicine for nucleic-acid delivery.
Nanocarriers can encapsulate and/or entrap hydrophilic and hydrophobic drugs,
modulate their release and distribution, improve drug mucosal and cell absorption and
protect them from degradation [10]. Nanoparticles (NP)-based drug delivery systems
(DDS) provide several advantages, as, owing to their extremely small size, they can easily
accumulate into rapidly growing tumor masses. Their specific cell uptake and trafficking
mechanisms allow active substances to be delivered to the target site in sufficient concen-
trations, thus decreasing the amounts that accumulate in undesired tissues/organs [11].
It is well known that the delivery of nanocarriers to tumors can be achieved via
two targeting strategies, passive and active targeting [12]. The first allows nanocarriers
to accumulate in the tumor tissue via the enhanced permeability and retention (EPR)
effect [5], which also depends on the physical properties (i.e., size, conformation) and
surface characteristics of the nanocarriers that, consequently, must be properly designed.
Furthermore, passive targeting is limited because the EPR phenomenon in tumoral tissue is
conditioned by the heterogeneity between tumor types, low or absent tumor uptake and/or
retention and the differing permeability of vessels throughout a single tumor. Moreover,
high interstitial pressure and the dense stroma structure often limit the homogeneous
intratumoral distribution of nanocarriers, compromising the therapeutic effect [13].
The second strategy, active targeting, aims to overcome these limitations by modifying
nanocarriers so that they actively bind to specific tumor cells or microenvironments. It
mainly consists of the delivery of NPs to the tumor site thanks to target-site recognition
by ligand molecules on the surface and an interaction with a highly expressed specific
cell-surface receptor [14].
This is achieved by decorating the nanocarrier surface with ligands that bind to recep-
tors that are overexpressed on tumor cells, thus improving the affinity for the cancer-cell
surface and/or the cancer microenvironment, and enhancing drug penetration and accu-
mulation in the tumor region. Moreover, NP platforms possess potential multifunctional
interactions with both ligand and drug molecules, the latter of which are able to interact
with NPs either chemically, via electrostatic and/or hydrophobic interactions, or physically,
being dissolved or entrapped in the NP matrix. Ligands are highly specific for target
cells/tissues. Moreover, several molecules can be attached to the nanocarrier simultane-
ously to increase binding to the target. The first evidence of this phenomenon was proposed
in 1980 when antibodies were grafted onto the surface of liposomes [15]. Although ligands
of different types have been proposed and used over time to target nanocarriers actively,
an optimal targeting strategy has not yet been identified, as each has its advantages and
disadvantages. The search for other molecular targets will improve delivery to the tumor
area by reducing toxicity to normal tissues [16]. Perhaps, a combination of strategies may,
in the future, be exploited to improve the accuracy of drug delivery, paving the way for
more effective personalized therapy [17].
It should be noted that the performance of targeted anticancer nanomedicine signifi-
cantly depends on the properties of the vehicles (size, surface charge, stability, degradability,
safety, etc.), the ligands (nature, chemical binding, density, availability, etc.), the therapeutic
agents (type, target, loading and efficiency, release, etc.) and other indications (tumor
category, volume, stage, receptor density, heterogeneity, accessibility, etc.), with all of the
factors intimately interacting with each other [2].
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In various studies, both in vitro and in vivo, it has been shown that nanocarriers that
are intended for active targeting achieve the selectivity of uptake by tumor cells through
endocytosis and/or receptor-mediated cytotoxicity of traditional drugs or other active
compounds such as nucleic acids and products of plant origin [18]. However, some of
the disadvantages of actively targeted nanocarriers should also be mentioned. Firstly, it
must be noted that their clinical use is limited to some types of cancer that express specific
receptors on their cell surfaces. Furthermore, the production of targeted nanocarriers is
expensive and requires appropriate technology [18].
Despite the considerable interest in this research area, and many successful nonclinical
trials, only a few passively targeted nanocarriers have been approved by the regulatory
agencies for cancer treatment, and no actively targeted nanocarriers have achieved this
recognition [11,12].
Anyway, several nanosystems are undergoing clinical trials [19] and have shown
promise for drug delivery to a variety of tumors. Most are either liposomal or polymeric,
while other typologies of nanocarriers are likely to enter clinical trials in the near future, as
many materials have already been deeply investigated in non-clinical tests.
Despite the exposed criticisms, there is no doubt that active receptor-based targeting
has the potential to be the first-choice release strategy, and interest in the development
of this kind of system has therefore significantly increased, both in terms of diagnostic
applications and therapies. It is important to underline that the synergy between active
and passive targeting is a good solution with which to promote nanocarrier accumulation
to a desired site, particularly a tumor. The active cancer-targeting approach, being comple-
mentary to the EPR effect, is a promising tool that can improve the specific localization of
both drug and carrier, and thus avoid healthy tissues and minimize off-target payloads
by exploiting nanocarrier engineering [20,21]. This strategy can significantly increase the
amount of a drug that is delivered to a target, compared to free drugs or passive targeting.
It thereby enhances therapeutic efficacy and limits adverse effects.
Many research groups worldwide are working on actively targeted nanocarriers, and
several of them are located in Italy, and include researchers from a range of disciplines,
including chemists, physicists, engineers and pharmacists. The aim of the present review
paper is to highlight the results of the last group, discussing the most representative
examples of Italian research carried out by many Pharmaceutical Technology academic
groups on the development of actively targeted NPs for cancer therapy purposes over
the last 10 years. We decided to restrict the framework of this paper to Italian academic
research, well aware that many non-academic research centers deal with this field, as we
would prefer to highlight the strengths of Italian academic research and the role it fulfills
in the national and international scenes.
A second, certainly no less important, aim of the present review paper is to underline
how the advanced progress in nanocarrier-based active targeting to fight cancer is strictly
related to interdisciplinary approaches and integrative dynamics in different research fields,
involving collaborations between numerous Italian technology groups and EU and/or
extra EU groups.
After a section describing some of the main active-targeting strategies, which will
provide some context, we decided to structure the review around two main topics: polymer-
based and lipid-based nanocarriers. Polymeric NPs and polymer-shelled nanobubbles are
included in the former, while the latter comprises liposomes, niosomes, lipoplexes, solid
lipid nanoparticles (SLNs) and squalene (SQ) NPs. Inorganic NPs, NPs for diagnostics
and imaging, drug-nanocolloids, polyelectrolyte nanocapsules and stimuli-responsive
NPs are not within the scope of this review, although they play an important role in
cancer nanomedicine.
2. Ligands for Active Targeting and Receptor-Based Active Targeting Strategies
The presence of several physiological barriers and the heterogeneity of the cancer-cell
microenvironment render the active-targeting approach more complex than the EPR-based
Pharmaceutics 2021, 13, 1538 4 of 30
one. Specific homing, enhanced retention at the target site and uptake by the target cells
are the main aims of active targeting. The search for suitable anticancer targets is on-going
because of the heterogeneous and adaptive nature of most tumor types [22].
A receptor can be exploited in ligand-target therapy only if it is present at a high
density on pathological cells, but almost absent or inaccessible on normal ones. Moreover,
it must have high specificity for the ligand and should have the ability to be internal-
ized and recycled back to the cell surface for another round of ligand binding and the
endocytosis process.
Ligands can easily attach to the receptors expressed on cancer cells and can mediate
nanocarrier delivery and accumulation inside the tumor site, mainly via receptor-mediated
endocytosis. Then, the drug can be released into the site for the therapeutic effect; the
delivery capacity of nanocarriers is directly related to their structure and composition [14].
A broad range of ligands are used to decorate the nanocarrier surface, and these belong
to the families of small molecules, carbohydrates, peptides, proteins and growth factors;
ligands can be roughly classified as peptide-protein ligands and non-peptide ligands.
2.1. Peptide-Protein Ligands
Antibodies (Ab) are 150 kDa large Y-shaped multi-chain proteins and are the most
commonly used peptide-ligands for decorating nanocarriers. Thanks to the differentiation
of light and heavy chains by the variable sequences present at the tips of the protein, infinite
specific and selective sites can be created to target an antigen/receptor that is overexpressed
on tumor surfaces efficiently [23]. As their large size results in low tumor-cell penetration
and quick elimination by the mononuclear phagocytic system (MPS) via non-specifically
binding, fragments of Ab have also often been proposed for enhanced specificity against
antigens or receptors that are overexpressed on tumor surfaces [24]. Various Ab and Ab
fragments include the epithelial growth factor receptor (EGFR) antibody and monoclonal
antibodies (mAb), raised against CD20, CD47 and Fas, to decorate the nanocarrier surface.
Peptides that are used as ligands offer many advantages in cellular targeting thanks
to their small size, precise chemical structure, biocompatibility and stability [25]. Moreover,
they are easy and cost-effective to produce in large amounts with high purity, and their
proteolytic degradation can be prevented by chemical modification.
Transferrin (Tf) is a glycoprotein that regulates iron levels in bodily fluids by binding
and sequestering it. Tf-loaded iron is internalized into cells by Tf receptor (TfR)-mediated
endocytosis; lactoferrin (Lf) is a mammalian cationic iron-binding glycoprotein that belongs
to the Tf family [26].
2.2. Non-Peptide Ligands
Molecules that are non-peptides are grouped together in this category; the most com-
monly used to decorate nanocarriers to target cancer cells specifically are aptamers, folic
acid (FA), carbohydrates and polysaccharides. Non-peptide aptamers are short oligonu-
cleotide sequences of either sRNA or DNA that are synthesized in vitro and that can
interact with a variety of targets with high affinity and specificity. FA (vitamin B9) is a
small, safe, non-immunogenic molecule that is essential for vital cellular activities such as
DNA synthesis, cell division, growth and cell survival, especially in highly dividing cells
or cancers. It can rapidly penetrate solid tumors, and it is easily available to form chemical
conjugations with other molecules [17].
Galactose has an affinity for asialoglycoprotein receptor (ASGPR), which is overex-
pressed on the surface of liver cancer, meaning that it is used as a ligand.
Hyaluronic acid (HA), a naturally occurring biodegradable, biocompatible, negatively
charged glycosaminoglycan, plays a crucial role in cell adhesion, migration, invasion,
proliferation, differentiation and angiogenesis by binding to specific cell receptors, mainly
glycoprotein CD44. It is available in a wide range of molecular weights, and its conjugation
to nanocarriers has been widely used to develop HA-based targeted therapy and translate
engineered nanocarriers into therapy.
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In accordance with bisphosphonate-based bone-targeted therapy, alendronate and
other bisphosphonates have been described as targeting agents for synergically targeting
bone tumors and metastases [27,28].
After describing the most frequently used ligands for NP active targeting, a short men-
tion must be given to a few receptor-based active-targeting strategies that must certainly
be mentioned alongside the description of most important receptors.
2.3. Human Epidermal Growth Factor Receptor (HER)
This is a broad family that includes four components, EGFR (HER1), HER2, HER3 and
HER4, and is assigned to receptor tyrosine kinase (RTK) type I. It has an important role in
the control of key signaling pathways that are related to cancer-cell growth, proliferation,
migration and survival. According to the assessment that EGFR is often overexpressed
in epithelial tumors, such as in squamous cancer of the head and neck region [29–32],
as well as in pancreatic, renal, colon, brain, ovarian and breast cancers, EGFR was the
first receptor to be proposed as an interesting therapeutic target for cancer therapy, and,
therefore, several promising nanoplatforms, which are based on the use of inhibitors
of these factors (i.e., tyrosine kinase inhibitors), ranging from small molecules to even
monoclonal antibodies, have recently been developed [15].
2.4. CD44 Receptor (CD44)
The CD44 receptor is a cell-surface adhesion non-kinase transmembrane receptor,
which mainly binds the ubiquitous component of the extracellular membrane hyaluronan
or HA with high affinity [33]. It has also been recognized to bind to several other ligands
including osteopontin, collagens and matrix metalloproteinases. It is overexpressed in
several cancer cells, such as lung, breast, colon, prostate, head and neck [34], and regulates
metastasis via the recruitment of CD44 to the cell surface. HA is considered as the main
ligand for CD44 and can bind ubiquitously expressed CD44 isoforms.
2.5. Folate Receptor (FL)
FL is present in humans as four isoforms (FRα, Frβ, FRγ and FRδ) and is a cysteine-
rich cell-surface glycoprotein receptor. It is overexpressed in cervical, epithelial, breast,
lung, ovarian, kidney, colorectal and brain tumors. FRα provides the potential for active tar-
geting strategies, allowing both tumor localization and the specific delivery of therapeutic
agents to the malignant tissue. FR is capable of binding to FA, and several FA-conjugated
nanocarriers have therefore been developed. The selective uptake of FA-surface modified
drug-loaded nanocarriers occurs through FR, and the cell-surface receptor–ligand complex
is transported into the cell via receptor-mediated endocytosis for ligand release [35,36].
2.6. Prostate-Specific Membrane Antigen (PSMA)
PSMA is a type II transmembrane glycoprotein with folate hydrolase activity that is
overexpressed in prostate cancer cells and, therefore, is an excellent target for imaging and
therapy. It has been largely investigated as a potential antigen for specific direct vascular
tumor targeting and exploited to engineer drug-loaded NPs with a PSMA ligand [37].
Although it has been recognized as a highly promising target, mainly for diagnostic
applications [38], several authors have recently developed highly specific targeting agents
for PSMA, which enable target-specific drug delivery to be performed [39].
2.7. Transferrin Receptors (TF)
The iron-free form of Tf, apotransferrin, forms Tf upon binding to Fe3+, then binds to
Tf receptors, TfRs, that are located on the cell surface, and then it enters the cell [40]. It has
been shown that TfRs are overexpressed, 2–10-fold, in most tumor cells, including breast,
lung, brain, liver, ovarian prostate and colon cancer cells, and are directly involved in the
process of iron homeostasis and cell proliferation, making them attractive and effective
targets for site-specific antitumor drug delivery [41]. TfRs are therefore interesting targets in
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the development of ligand-based nanotherapies that involve the natural ligand Tf, mAbs or
single-chain variable fragments (scFv) [42,43]. The Tf approach has been most thoroughly
investigated for drug delivery to the brain, as the Tf ligand facilitates transcytosis of the
conjugated drug-carrier systems across the blood brain barrier (BBB). TfR targeting has
also been successfully exploited in ovarian carcinoma [44] and used to overcome multidrug
resistance (MDR) in breast cancer [45].
2.8. Biotin-Specific Receptors
Biotin is an essential micronutrient that can be exploited to provide tumor-targeting
properties to nanocarriers, thanks to the overexpression of biotin-specific uptake sys-
tems [46], which have recently been found to be enhanced in many cancer cells lines,
including ovarian, leukemia, mastocytoma, colon, renal and breast. For these reasons,
many examples of biotin being used as a targeting moiety in tumor therapy, both for
therapeutic and diagnostic/theranostic purposes, have been reported in the literature [47].
2.9. Interleukin Receptor
The therapy of malignant gliomas, due to their complexity and the existence of the
BBB, which hinders the accumulation and uptake of endogenous substances in tumors,
remains a challenge despite the recent improvements. The advances in targeting technology
and breakthroughs in the overexpressed receptor derive from the discovery of interleukin
receptors, such as IL-13RA2, in gliomas. The discovery of such a receptor creates a bench-
mark in drug delivery and targeting with encouraging output in clinical investigations [48].
The discovery of interleukin-receptor overexpression on glial tumors drove the use of an
interleukin 6 receptor binding peptide as a targeting ligand for DNA-loaded NPs [49].
2.10. Insulin (INS) and Nnsulin-like Growth Factor (IGF) Receptors
INS and IGF in physiological conditions exert a specific function—glucose metabolism,
and cell growth and proliferation, respectively—whilst both receptors produce similar bio-
logical functions in cancer conditions, sharing a signaling pathway that plays an important
role in cancer development and progression. For this reason, both receptors have emerged
as targets for cancer therapy [50].
Far from being an exhaustive list of the different ligand-receptor strategies that have
been exploited by Italian researchers and that will be described in this review, this chapter
is intended to emphasize the fact that the search for good anticancer targets and targeting
ligands continues and is strongly stimulated by the heterogeneous and adaptive nature of
many tumor types.
3. Ten Years of Italian Research on Actively Targeted Nanocarriers
3.1. Polymer-Based Nanocarriers
Polymer-based nanocarriers encompass a large variety of nano-sized colloids that are
formed by natural or synthetic polymers into which a drug is either physically dispersed,
dissolved or chemically bound to the polymer structure (Figure 1).
In most cases, the associated drugs are lipophilic, but hydrophilic compounds can
also be incorporated by tuning the nanocarrier structure. Polymers have attracted much
attention in the drug-delivery field thanks to the diversity of the available polymer sources,
their composition and the synthesis procedures that allow the macromolecular structure to
be engineered to be biocompatible, biodegradable and to contain derivatizable functional
groups that are available for linkage to different homing agents. The accurate design of
polymers influences the characteristics of the nanocarriers, such as their size, morphology,
surface charge, drug loading mechanism and release mechanism [51].
Polymers are also frequently used to coat inorganic NPs to increase their biocompat-
ibility and facilitate covalent coupling with specific targeting ligands. Nevertheless, as
already mentioned, inorganic NPs are not considered in this review.
Pharmaceutics 2021, 13, 1538 7 of 30
Figure 1. Schematic representation of most common actively targeted nanocarriers developed by
Italian Technology research groups using ligand-based strategies over the last 10 years.
Concerning the use of FA as a targeting agent for natural polymer-based actively
targeted nanocarriers, the vitamin was coupled to chitosan (CHIT) via an amide linkage.
Methotrexate (MTX)-loaded NPs were then obtained using an ionotropic gelation technique.
In the presence of high concentrations of reductive agents in cancer-cell microenvironments,
these multifunctional NPs have shown redox-responsive drug release via the conjugation of
L-cysteine to CHIT. The presence of FA moieties on targeted NPs provided higher selectivity
towards FR-overexpressing HeLa cells, compared to untargeted nanocarriers [52].
Other stimuli-responsive nanosystems have been prepared from triblock copolymers
formed of two terminal hydrophilic blocks (polyethylene glycol (PEG) and polyglycerol-
methacrylate (poly-GMA)- and a central weakly basic block (polyimidazole-hexyl methacry-
late (poly-ImHeMA)). In these polymerosomes, the central part was able to complex
oligonucleotides, while the imidazole-containing side chains conferred pH-responsiveness
to control carrier formation/disassembly. FA was linked to the copolymer, via an amide
linkage, and a mixture of targeted and untargeted chains was used to prepare poly-
merosomes that were tested in vitro. The results showed a 5.5-fold higher uptake of
double-strand-DNA-loaded folate-polymersomes in KB cells, compared to the untargeted
ones [53,54].
A mixture of dextran (DEX) amphiphilic derivatives has been proposed as a means to
obtain FA-targeted and pH/redox-responsive NPs. In more detail, DEX was conjugated
to FA via esterification (DEXFA) and, separately, to PEG (DEXssPEGCOOH). The two
derivatives self-assembled into NPs that could be destabilized in acidic pH and reducing
media. In addition, encapsulated doxorubicin (DOX) showed a higher cytotoxic effect in
FR+ cells [55].
When large molecules, such as PEG, are added onto the NP surface, the exposition
of the targeting agent can be affected and, sometimes, hindered, especially for small
ligands, such as FA. Thus, NPs have also been prepared via solvent displacement using
mixtures of PEG-poly(ε-caprolactone) (PEG-PCL), with different PEG chain lengths (1.0
kDa or 2.0 kDa), and a FA-functionalized PEG-PCL (PEG 1.5 kDa), which was obtained
via click-chemistry. The presence of shorter PEG chains allowed FA to be more exposed
on the NP surface and assured, at the same time, reduced uptake by human macrophages
and the higher uptake of targeted NPs by KB (FR+) rather than A549 (FR−) cells [56].
In another approach, the effective exposition of FA on NPs was evaluated by preparing
core-shell FA-targeted NPs in a melting/sonication procedure using diblock copolymers
of PCL and PEG and by adding (2-hydroxypropyl)-β-cyclodextrin (HPβ-CD) during the
nanoassembly procedure. The interaction of HPβ-CD with the FA moieties allowed FA to
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be more highly exposed on the NP surface and, consequently, a higher uptake in cells that
overexpress FR was achieved [57]. In a further development, FA exposure was obtained
via the conjugation of the ligand to a PEG chain that was threaded with αCD in a single
step reaction. In this original, selectively rotaxanated copolymer (Fol-PEG(αCD)-b-PCL),
the presence of αCDs on the PEG chains led to a more extended conformation in the
chains, which exposed the FA moieties after nanoprecipitation and, thus, promoted cellular
uptake in FR-overexpressing cells compared to non-targeted NPs and the corresponding
non-rotaxanated targeted carriers [58].
As far as the preparation of HA-decorated polymer NPs is concerned, different strate-
gies can be exploited, such as HA-conjugate synthesis, the coating of NPs with HA, chemical
cross-linking and ionotropic gelation.
Among natural polymers, CHIT has been thoroughly investigated and HA-decorated
NPs have been produced via ionotropic gelation, by exploiting the electrostatic interactions
between the positively charged amino groups of CHIT and negatively charged HA. The
molecular weight and concentration of both the polymers, the CHIT degree of deacetylation,
pH and temperature are the key parameters in formulation design, and they affect the
NP physico-chemical characteristics and HA localization in the NP structure. A one-
step inverse ionotropic gelation method was developed to optimize the deposition of
HA on the NP surface [59]. The above-mentioned method was recently improved using
microfluidics, and reproducible HA-decorated CHIT-based NPs with tailored-made narrow
size distribution were obtained [60]. These NPs were avidly internalized in CD44+ human
mesenchymal stem cells via CD44 receptor-mediated endocytosis, as demonstrated in
competitive cellular binding experiments. Interestingly, the HA-CHIT NPs were able
to load everolimus efficiently, and showed high cell-proliferation inhibition in CD44+
cells [60].
Albumin is another natural polymer that has been employed as a promising ma-
terial in cancer therapy. Human serum albumin was used for the manufacturing of
DOX-loaded micelle-like NPs [61]. They were prepared by the self-assembling of a HA-
human serum albumin conjugate, obtained via their covalent coupling with 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC).
In addition, the insertion of cystamine moieties in the nanostructure using a cystamine-
modified HA conferred redox-responsive functionalities. An increase in DOX release from
albumin NPs was observed in the presence of a higher GSH concentration (10 mM),
confirming the redox-responsive behavior. Moreover, the DOX-loaded NPs exhibited a
CD44 receptor-mediated cell internalization mechanism in metastatic cancer (MDA-MB-
231) cells, which was associated with a higher cytotoxic effect compared to the free drug.
Poly(lactic-co-glycolic acid) (PLGA) is one of the most commonly investigated poly-
mers for anticancer DDS thanks to its biodegradability, biocompatibility and safety profile.
In addition, it is FDA-approved for pharmaceutical applications and human administration.
Concerning the development of actively targeted PLGA NPs through HA, this polysac-
charide was often used as a coating material. For example, HA-coated PLGA NPs have
been formulated for the delivery of sclareol, a phytochemical compound with anticancer
properties [62]. PLGA NPs were obtained using the nanoprecipitation technique and
then coated with high molecular weight HA (1500 kDa) via incubation. The HA coating
increased the antitumor efficacy of the sclareol-loaded formulation against human breast
cancer cells that expressed the HA receptors (MCF-7 and MDA-MB468), compared to the
uncoated formulation, as it promoted cell interactions and the intracellular localization of
the nanosystems.
Other studies have reported PLGA NPs being used as a core template and then
surrounded by purposely designed shells that are endowed with the ability to target
CD44 receptors. In particular, a polymer shell of low molecular weight HA (<10 kDa) and
polyethyleneimine (PEI) has been built onto PLGA NPs using the layer-by-layer deposition
technique, by exploiting the electrostatic interactions between oppositely charged polymers.
HA/PEI-decorated NPs have demonstrated the capability to load docetaxel (DTX) to a
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great extent and release the encapsulated drug in a sustained manner [63]. Moreover,
in vitro studies have demonstrated the enhanced uptake of rhodamine labeled HA/PEI-
decorated PLGA NPs in CD44+ lung cancer cells and improved DTX cytotoxic activity,
compared to the free drug. Intriguingly, this versatile nanostructure can be designed for
the co-delivery of drug combinations by taking advantage of the shell and core properties.
A polymeric nanoplatform, based on a core of PLGA and a polymer shell of HA
and PEI, has been proposed for the co-delivery of 5-fluorouracil (5-FU) and a plasmid
that encodes the proapoptotic protein L3 (pL3) in the treatment of colon cancer [64]. The
combined NPs enhanced 5-FU anticancer activity by increasing the chemosensitivity of
human colon cancer cells. This tumor-selective chemosensitizer effect was due to the
induction of apoptosis and the control of the drug efflux through the regulation of P-gp (P-
glycoprotein) pump expression by L3 [58]. These HA-decorated double-coated PLGA NPs
have recently been further investigated for the co-delivery of DTX and photosensitizers,
such as disulfonate tetraphenyl chlorin and anionic porphyrin (TPPS4), to give targeted
nanotools for combined chemo- and photodynamic therapy [65–67].
Moving now to the active targeting of polymer nano-sized carriers via biotin, mixed mi-
celles made of Pluronics P123/F127 (synthetic triblock copolymers containing hydrophilic
and hydrophobic regions) have been prepared using the thin-film hydration method to
load repurposed drugs, such as the anthelmintic niclosamide and the photosensitizer
verteporfin, that have been proposed for the treatment of multidrug resistant non-small
lung cancer and locally advanced pancreatic cancer, respectively [68–70]. Biotin was first
conjugated to Pluronic F127 via an ester bond. Then, the derivative was used to prepare
the mixed micelles, which showed higher uptake in cancer cells than untargeted carriers
and provided gradual drug release, at the same time.
Peptides and proteins have been conjugated to polymer NPs as well. In particular,
an antiangiogenic peptide has been associated to an anticancer agent, namely DTX, in
a combined approach, and tested in triple negative breast cancer cells. In more detail,
DTX was incorporated into the inner part of PEG-PCL NPs using the nanoprecipitation
technique, while an anti-vascular endothelial growth factor receptor 1 (anti-VEGFR1)
hexapeptide was conjugated, via click-chemistry, to the PEG hydroxyl groups before NP
formation. The combination of the loaded drug and the exposed peptide enhanced the
antiangiogenic and in vivo anticancer effect in a xenografted mouse model of a MDA-
MB231 tumor [71].
Antibody-engineered drug-loaded polymer NPs have been obtained from a different
synthetic copolymer by conjugating rituximab, a chimeric monoclonal antibody that is
targeted against the marker CD20, to PLGA. NPs were prepared using the oil-in-water
single emulsion-solvent evaporation technique and loaded with Nutlin-3, a nongenotoxic
activator of the p53 pathway. While Nutlin-3-loaded targeted and untargeted NPs did not
show a significant difference in the activation of the p53 pathway in p53 wild-type JVM-2
leukemic cells in in vitro tests, actively targeted Nutlin-3-containing nanocarriers displayed
the highest therapeutic activity in terms of survival rate in vivo [71]. Nutlin-3-PLGA NPs
have also been formulated, via nanoprecipitation, and conjugated to the human mono-
clonal antibody against CD-138/Syndecan-1 (anti-Syndecan-1) to target primary effusion
lymphoma. Again, targeted NPs showed increased selectivity compared to untargeted
carriers [72].
In another approach, PLGA NPs that were loaded with curcumin (CUR) were pre-
pared using the single emulsion solvent evaporation technique and then surface-coated
with different molecules: CHIT for adhesion to the gastro-intestinal mucosa; wheat germ
agglutinin for colon targeting; the GE11 peptide for colon tumor targeting. The NP surface
was decorated with CHIT via coulombic interaction, since it is a polycationic mucoadhesive
polysaccharide that adsorbs onto the negatively charged PLGA surface, and via covalent
linkage for wheat germ agglutinin and GE11. Results showed that, depending on the
coating, NPs were taken up by the cells via different mechanisms, notably by electrostatic
interaction for CHIT and specific active mechanisms for both wheat germ agglutinin and
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GE11 [73]. GE11-PLGA NPs were also obtained via the nanoprecipitation of a blend
(1:1 weight ratio) of two different PLGA-based polymers. In the first, GE11 was covalently
coupled to PLGA, while, in the second, PLGA was functionalized with PEG. The obtained
NPs showed low cytotoxicity, high stability in plasma and an efficient targeting ability
towards EGFR-overexpressing cancer cells. Furthermore, GE11-PLGA NPs were able to
incorporate a hydrophilic model drug into the particle matrix [74].
PLGA NPs have also been conjugated to synthetic ligands of the translocator protein
18 kDa (TSPO), a mitochondrial protein that is overexpressed in many cancer types. These
ligands, characterized by a 2-phenyl-imidazo-[1,2-a]-pyridineacetamide structure, possess
pro-apoptotic activity that was combined with the anticancer mechanism of 5-FU through
the incorporation of the drug into NPs that were prepared via a quasi-emulsion solvent
diffusion method. The results of the in vitro tests, carried out on C6 glioma cells that
overexpressed TSPO, showed that a synergistic effect occurred [75]. The same ligands
have been conjugated to fourth generation poly(amidoamine) (G(4)-PAMAM) fluorescent
dendrimers and tested in the same cell line in the presence of various endocytosis inhibitors
in order to investigate the cellular-uptake mechanism of the targeted nanocarriers. The
dendrimers were found to be quickly internalized by pinocytosis and directed towards
the mitochondria, as demonstrated by subcellular fractionation and confocal microscopy,
together with competition studies [76]. The versatile G(4)-PAMAM dendrimer has also been
linked to lactobionic acid, which targets the asialoglycoprotein receptor; after conjugation
with a fluorescent moiety and loading with sorafenib, targeted dendrimers displayed
higher binding and uptake ability in the asialoglycoprotein receptor-expressing human
liver-cancer cell line, HepG-2, compared to non-expressing HLE cells [77].
The bisphosphonate, alendronate, has been conjugated onto the surface of PLGA NPs
in order to target anticancer drugs (such as DOX) towards skeletal tumors [78]. In vitro as-
says on human osteoclasts showed that the active targeting of PLGA NPs with alendronate
enables the antiosteoclastic effect of the conjugated bisphosphonate to contribute to the
inhibition of tumor-associated bone degradation [79]. Conjugation with alendronate was
also applied to dendrimers; heterobifunctional PEG was linked to paclitaxel (PTX) and
alendronate, forming amphiphilic derivatives that self-assembled into nanocarriers that
simultaneously possessed the binding affinity for the bone mineral hydroxyapatite and the
cytotoxic activity of PTX against PC3 prostate-cancer cells [80].
Polymer-Shelled Nanobubbles (NBs)
NBs are another polymer nanoplatform that have been studied for the active targeted
delivery of anticancer drugs. NBs are core-shell nanostructures consisting of a core, made
up of a gas or a vaporizable compound, surrounded by a shell (Figure 1). They are
considered to be the next generation of microbubbles, and they are already in clinical
use as contrast agents for ultrasound (US). Unlike microbubbles, NBs have a prolonged
circulation time and can extravasate from blood vessels, but remain visible to US imaging.
They are therefore considered theranostic nanocarriers due to the double function of being
US-triggered DDS and US-imaging agents. They have been proposed as promising vehicles
for the delivery of drugs, genes and gases [81].
Polymer-shelled NBs have attracted great research attention due to the ability of the
shell to enhance stability and be engineered with ligands for active targeting. Biodegradable
polymers, either synthetic or natural, have been used as shell components and functional-
ized for ligand-receptor-mediated tumor targeting.
FA-conjugated PLGA-PEG NBs that encapsulate DOX have shown marked accumu-
lation in tumor sites in a biodistribution study on breast-cancer-bearing balb-C mice [82].
Moreover, Lf that was conjugated to poly(l-lactic acid) (PLA) NBs has shown increased
affinity in vivo in tumor-bearing mice [83].
Antibody-linked NBs have also been reported in the active targeting of anticancer
drugs. PLGA NBs were bound to the humanized HuCC49DCH2 antibody, and were shown
to be able to target the over-expressed TAG-72 antigen in vitro [84]. The conjugation of
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MTX-loaded NBs to monoclonal anti-HLA-G antibodies is another example that has given
promising results both in vitro and in vivo [85].
NB technology has been developed and investigated in the Italian research scenario.
Interestingly, purposely tailored CHIT-shelled NBs have been developed for the delivery of
antagomiR17 as a therapeutic option for Burkitt lymphoma treatment, using nanoemulsion
as the template. The targeted NBs were prepared via the conjugation of rituximab, by
means of reductive amination, to the CHIT shell of the preformed NBs. The targeting agent
promoted the internalization of antagomiR17-loaded NBs into CD20-expressing cancer B
cells, and enabled the anticancer effect to be exerted. In fact, the inhibition of tumor growth
was achieved after the administration of targeted NBs to a human-SCID model of Burkitt
lymphoma, while no therapeutic effect was observed when using untargeted NBs [86].
In addition, CHIT-shelled NB formulations have been proposed as an innovative im-
munotherapeutic platform for the treatment of HER2+ breast cancer. NBs were conjugated
with anti-CD11 antibodies to target dendritic cells (DCs), and loaded with a DNA vaccine.
The targeted pHER2-loaded NBs were able to induce the activation of DCs and elicit a
specific anticancer immune response, delaying tumor growth in vivo [87].
3.2. Lipid-Based Nanocarriers
Liposomes are spherical nanovesicles that consist of natural or synthetic phospho-
lipid bilayers surrounding a water core (Figure 1). Liposomes are spontaneously formed
when phospholipids are dispersed in water. As phospholipids are the major component
of liposomes, they are nontoxic, biodegradable and biocompatible. Moreover, they are
biologically inert, weakly immunogenic, and they have low intrinsic toxicity. They can
encapsulate a wide variety of drugs. Whether the drug is encapsulated in the aqueous core
or in the surrounding bilayer of the liposome is dependent on the characteristics of the
drug and on the encapsulation process. In general, lipophilic drugs are entrapped almost
completely in the lipid bilayer, hydrophilic compounds are encapsulated in their aqueous
core and amphiphilic drugs partition between the lipid and aqueous phases, both in the
bilayer and in the aqueous core [88,89]. A number of liposomal formulations are on the
market for the treatment of different therapeutic applications [90].
Liposomes that co-encapsulate DOX and sorafenib and are decorated with the LinTT1
peptide, a specific molecule that targets the p32 protein, which is overexpressed by breast
cancer and cancer associated cells, have been prepared and characterized [91]. The peptide
was inserted onto the surface of preformed liposomes. The in vitro activity of the liposomes
was evaluated in both positive estrogen receptor (MCF-7) and triple negative breast cancer
(MDA-MB-231) cells in 2D and 3D cellular models. The results showed that the uptake and
cytotoxicity of the LinTT1-functionalized liposomes was higher than that of plain liposomes
and a combination of free drugs. Moreover, the LinTT1-functionalized liposomes were
partly internalized and partly associated to the external cell membranes of primary human
M2 macrophages, suggesting that there may exist a mechanism to modulate the penetration
and accumulation of LinTT1-decorated liposomes in the central portion of the hypoxic area
of tumors.
A new loading method, based on the use of a complexing agent already entrapped
inside the liposome compartment (amino-lactose), has been developed for the efficient
encapsulation of bortezomib (BTZ) in the aqueous core of liposomes with the aim of form-
ing a boronic ester between the boronic acid moiety of BTZ and the hydroxyl groups of
amino-lactose. A NGR-motif-containing peptide was then linked to the liposome surface
as a targeting ligand for the tumor endothelial cell marker to target aminopeptidase N-
positive tumor vessels [92]. The formulations were characterized in terms of encapsulation
efficiency, drug release, size and Zeta-potential value. In vivo experiments were performed
in orthotopic-neuroblastoma-bearing mice and showed that liposomal formulations pro-
vided a significant reduction in systemic adverse drug effects and that the presence of
the peptide on the surface of liposomes improved the ability of BTZ to decrease neurob-
lastoma cell growth [93]. A similar approach was previously used for the preparation of
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liposomes that were decorated with NGR and encapsulated the apoptotic and antiangio-
genic drug, fenretinide, which has been proposed as an adjuvant tool in the treatment of
neuroblastoma [94].
Liposomes that can target bombesin (BN)-receptor-overexpressing tissues have been
prepared for theranostic purposes. A new amphiphilic peptide derivative (MonY-BN)
that contained the BN(7–14) peptide, the DTPA (diethylenetriaminepentaacetate) chelating
agent, a hydrophobic moiety with two C18 alkyl chains and PEG spacers was synthesized
using solid-phase methods. MonY-BN was added to the phospholipid during liposome
preparation, and DOX was further encapsulated using the remote pH gradient method. Ra-
diolabeled control liposomes were prepared by adding trace amounts of 111InCl3. Several
analyses were performed to evaluate the liposome structure, drug-loading ability, in vitro
cellular binding and cytotoxicity and in vivo therapeutic efficacy. The results showed that
the simultaneous presence of both the peptide and the chelating agent should be able to
provide the targeting ability and allow radiolabeling for diagnostic purposes. [95]. In order
to enhance the activity of the system, the same group proposed a modified sequence of
the BN(7–14) peptide that contained a modified BN sequence (BN-AA1) that should yield
the desired high serum stability, high receptor affinity and act as a BN antagonist. The
decorated liposomes showed targeting abilities and improved cytotoxicity in PC-3 cells
and PC-3 xenograft-bearing mice. Although the results were quite similar to those obtained
using the BN(7–14) peptide, the authors suggested that the AA1 antagonist sequence
should provide safer working conditions for the further development of DDS [96]. The
same research group proposed the use, as a targeting moiety, of a cyclic peptide, named
Peptide R, which was identified as the most active of the recently proposed CXCR4 receptor
antagonists. The chemokine receptor CXCR4 is expressed in immune cells and overex-
pressed in tumor cells, where, upon binding to its ligand CXCL12, it plays a critical role in
invasion and metastasis in solid and hematological cancers and tumors [97]. DOX-loaded
liposomes were then decorated with Peptide R, via conjugation of the previously thiolated
peptide, and the maleimide-PEG chain on their surface. These liposomes were proposed for
combination therapy; the in vitro test showed that they were able to deliver DOX efficiently
and improve its cytotoxicity in CXCR4-expressing cell lines, while they were able to deliver
the drug to melanoma lung metastases in vivo efficiently and reduce metastasis formation
thanks to their antagonistic CXCR4 activity [98]. A similar conjugation method was used
for the preparation of urotensin-II (UT)-decorated liposomes that encapsulated DOX and
were able to bind the UT receptor overexpressed on colon, bladder and prostate cancer
cells [99]. In this paper, the cysteine residue that was inserted into the peptide reacted with
the PEG maleimide group on the liposome surface, and the targeting ability of the system
was confirmed in in vitro tests on prostate- (DU145, PC3 and LNCaP) and colon-cancer cell
lines (WIDR and LoVo). The cells showed different levels of UT-receptor expression, and
the results demonstrated that the activity of the decorated liposomes was higher in the
cells that overexpressed the receptor [100].
Acidity-sensitive vesicles (liposomes and niosomes) have been prepared by inserting,
into the hydrophobic region of the nanovector, a conjugate of 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine (DSPE) lipids and pH (low) insertion peptides (pHLIP). Studies
into the characteristics of the nanocarriers showed that the peptide is anchored and lies in
the external surface. They should interact with target membranes at the acidic pH of the
tumor microenvironment and release their content after bilayer rearrangement in low pH
environments [101].
The same research group previously proposed an in vivo biodistribution study of
fluorescently labeled pHLIP-coated niosomes in mice that bore 4T1 mammary tumors,
showing significant tumor accumulation, compared to the non-targeted niosomes, and
minimal kidney, liver and muscle accumulation [102].
The above-mentioned niosomes (non-ionic liposomes or non-ionic surfactant vesicles)
are non-ionic surfactant-based vesicles that are able to self-assemble into unilamellar
or multilamellar vesicles in aqueous media [103]. Non-ionic surfactants tend to orient
Pharmaceutics 2021, 13, 1538 13 of 30
themselves with the hydrophilic end facing the aqueous phase and the hydrophobic one
facing inwards towards each other to form a closed bilayer structure, which encloses
solutes in an aqueous solution (Figure 1). The formation of the closed bilayer structure
is rarely spontaneous [104], and usually involves energy such as physical agitation or
heat. Although not lipid-based, they are reported in this section due to their structural
similarity with liposomes. Niosomes were first reported in the seventies in the cosmetics
industry [105] but have been proposed as versatile and economic nanocarriers that are
able to encapsulate a wide range of drugs, also thanks to their low cost, great stability and
resulting ease of storing the non-ionic surfactants [106,107]. By varying the components,
in terms of type of surfactant, composition and concentration, it is possible to change the
features of the niosomes, including their size, surface charge and volume [108].
As already reported for polymer-based nanocarriers, HA has been proposed as a
ligand to improve the targeting ability of liposomes and lipoplexes. For this purpose,
conjugates between HA of different molecular weights and phospholipids have been
prepared, characterized and employed for the preparation of actively targeted nanocarriers.
Low-molecular-weight HA (4.8 kDa and 12 kDa) has been reacted with the aminated
lipid 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) via reductive amination
to produce conjugates that were added to the lipidic mixture during liposome preparation.
Only one lipid molecule is linked to HA in these conjugates. In order to propose this
system for the treatment of pancreatic adenocarcinoma (PDAC), which is characterized
by the high expression of the HA-specific receptor CD44, liposomes were loaded with a
lipophilic gemcitabine (GEM) prodrug. Liposomes were fully characterized in terms of
size, surface charge and morphology. Further in vitro and in vivo studies showed that all
of the liposome formulations were characterized by higher antitumoral activity than the
free drug. The 12 kDa HA liposomes had the strongest efficiency, while non-conjugated
liposomes and the 4.8 kDa HA liposomes were similarly active [109,110]. A novel system
that is targeted towards pancreatic cancer stem cells, which are known to be responsible for
resistance to standard therapy, has been developed to improve current therapies against
PDAC. In particular, diethyldithiocarbamate-copper-containing, HA-decorated liposomes
that were able to target the specific cancer stem cells marker CD44 receptor were prepared
using the ion-gradient technique and fully characterized. Their antiproliferative effect
was evaluated in pancreatic cancer stem cells that were either derived from PDAC cell
lines or patients, and strongly increased anticancer activity was observed, paving the
way for the development of nanomedicine-based cancer-stem-cell-targeting therapeutic
approaches [111].
The HA-DPPE conjugate has also been used for the preparation of decorated lipo-
somes that encapsulate a synthetic DOX that is conjugated with a H2S-releasing moiety
that was demonstrated to be less cardiotoxic and more effective than DOX against Pgp-
overexpressing osteosarcoma cells. HA liposomes showed a favorable drug-release profile
and higher toxicity in vitro and in vivo than DOX or Caelyx (commercial DOX-loaded PE-
Gylated liposomes) against Pgp-overexpressing osteosarcoma. Unlike DOX, HA-liposomes
delivered the drug inside the endoplasmic reticulum (ER), inducing protein sulfhydration
and ubiquitination, and activating an ER-stress pro-apoptotic response. HA-liposomes also
sulfhydrated the nascent Pgp in the ER, reducing its activity [112].
Recently, the targeting ability of new conjugates that were obtained by reacting
HA oligosaccharides (with a degree of polymerization, DP, of 4, 6 and 8) with a PEG-
phospholipid moiety was evaluated. The conjugates were employed for the preparation of
fluorescently labeled HA-DP-decorated liposomes that showed significantly higher (12- to
14-fold) cellular uptake in lung-cancer cell lines with high CD44 expression than in those
with low CD44 expression, suggesting that the formulations underwent receptor-mediated
entry. Moreover, uptake increased with increasing DP. HA-DP-decorated liposomes did not
show cytotoxicity or inflammatory effects, suggesting that these conjugates may be used
as biocompatible and effective tools for potential drug delivery to CD44+ cells [113]. The
above-mentioned lipoplexes are lipid-based non-viral vectors that have been proposed as a
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means to transfer nucleic acids, such as plasmid DNA, siRNA and mRNA, to treat a wide
range of disorders, from infectious and inherited diseases to cancer (Figure 1). They have
some attractive features compared to viral vectors, and these include their easy produc-
tion and chemical modification, low immunogenicity, safety and enhanced loading. They
are composed of positively charged lipids that can interact and bind negatively charged
nucleic acids. This electrostatic interaction between cationic non-viral vectors and the
negative charged phosphate groups leads to a compaction in the system. Moreover, the
presence of positive charges confers protection from nuclease attack and improves cellular
uptake [114,115].
High-molecular-weight HA (1500 kDa) has been coupled to 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE) by means of an amidation reaction in which the amino
group is randomly linked to the carboxylic residues of the polymer, and then introduced
into the lipoplexes during preparation [116]. The lipoplexes were prepared via the addition
of DNA to cationic liposomes, some of which contained the HA-DOPE conjugate, while
others did not and were characterized. In vitro studies on breast cancer cells indicated that
lipoplex cytotoxicity was not modified by the presence of the HA-DOPE conjugate, but
its presence increased the transfection efficiency on CD44+ MDA-MB-231 cells compared
to the CD44- MCF-7 line. The strong specificity of DNA targeting via the CD44 receptor
using high-molecular-weight HA as the ligand was demonstrated by the same authors in
the A549 lung-cancer cell line using a reporter plasmid that encoded the green fluorescent
protein [117].
The HA-DOPE conjugate was also used for the preparation of lipoplexes for the deliv-
ery of anti-telomerase siRNA to CD44+ lung-cancer cells. The targeted lipoplexes displayed
improved stability in the cell-culture medium and reduced cytotoxicity, without altering
the binding or protection of siRNA [118]. In another study, the ability of HA-decorated
siRNA lipoplexes was evaluated both in vitro and in vivo in a murine A549 metastatic
lung-cancer model, using an anti-Luc siRNA. The potential of the system was demonstrated
by the decrease in luciferase expression, which contrasts with the progressive increase ob-
served when using non-modified lipoplexes [119]. The structure and morphology of these
lipoplexes were investigated in detail using different techniques and approaches, includ-
ing radioactive labeling, diameter and surface charge analyses, capillary electrophoresis,
cryo-TEM microscopy, SAXS and surface plasmon resonance [120].
Tf has been used to decorate liposomes, niosomes and self-assembling lipid NPs.
The anticancer activity of the antimalarial sesquiterpene lactone artemisinin was explored
by encapsulating the compound in liposomes. Drug loading in nanocarriers was also
explored to improve its stability and solubility. Liposomes were then decorated with Tf to
obtain specific targeting towards cancer cells that overexpress TfRs. Tf was inserted onto
the surface of preformed liposomes via a coupling reaction between DSPE-PEG-COOH,
used as a linker lipid, and the free amino groups of the protein in the presence of EDAC.
The plain and decorated liposomes were characterized in terms of size, drug-entrapment
efficiency, Tf-coupled coupling moieties and stability. The targeting ability of Tf liposomes
was assessed in in vitro studies (cell uptake and cytotoxicity) on the human colon cancer
cell line HCT-8, which is characterized by the overexpression of TfR [121].
Novel hybrid self-assembling NPs (PLCaPZ NPs), based on calcium phosphate and
lipids, were developed to deliver zoledronic acid (ZOL) to different tumor models and
displayed superior delivery efficiency than PEGylated liposomes [122]. In order to improve
the targeting ability of PLCaPZ NPs towards glioblastoma, Tf was added during PLCaPZ
NP preparation to obtain Tf-PLCaPZ NPs. The structural characterization of the system
was performed using different techniques, including small angle neutron scattering, X-ray
scattering and cryo-electron transmission microscopy [123]. The efficacy of Tf-PLCaPZ NPs
was evaluated in different glioblastoma cell lines and in an animal model of glioblastoma
and was compared with PLCaPZ NPs and free ZOL. In vitro results in LN229 cells showed
significant uptake and the improved cytotoxicity of Tf-PLCaPZ NPs. The results obtained
in mice xenografted with U373MG revealed that Tf-PLCaPZ NPs had the highest anticancer
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activity [124,125]. Thiolated Tf, obtained via derivatization with 2-iminothiolane (Traut’s
reagent), was coupled with the preformed stable nucleic acid lipid vesicles (SNALPs)
that contained DSPE-PEG-maleimide, forming a stable thioether bond between lipid vesi-
cles and the ligand. miR-34a was encapsulated to target TfR-overexpressing multiple
myeloma cells. The vesicles demonstrated the ability to inhibit tumor growth in vivo, and
Tf-conjugation resulted in a significant prolongation of mouse survival [126].
Niosomes have been employed as nanocarriers for the active targeting of DOX in breast
cancer cells that overexpress TfRs (MCF-7 and MDA-MB-231). Niosomes were prepared
using, among other components, an opportunely modified Pluronic L64 surfactant that can
react with the protein. In particular, free Tf amino groups were linked to the carboxylic
groups of the carrier on the external surface of the niosomes in the presence of EDAC.
Niosomes were found to be regular in shape and homogeneous in size, and DOX was
easily encapsulated into them, without affecting vesicle morphology. The in vitro test on
fluorescently labeled Tf niosomes indicated that the nanocarriers were mainly taken up
by TfR-mediated endocytosis. When DOX was loaded, Tf niosomes showed a significant
reduction in viability in a dose- and time-related manner [127]. The same group proposed
an evolution of this approach by coupling either Tf, FA or a combination of the two
for the delivery of either DOX and CUR, or DOX and quercetin, into multifunctional
niosomes. In vitro experiments showed that the niosomes loaded with DOX/CUR had the
highest cytotoxic activity, confirming the synergistic effects of the combination. Finally, the
reduction in cell viability followed the trend; Tf, Tf-FA- and FA-niosomes. These results
may be due to the condensation reaction between the carboxylic groups of the surfactant
and the two different amino groups of FA, one of which may reduce the ligand-receptor
recognition required for cellular uptake [128].
Recent work by Italian research groups that used FA as a targeting ligand has not only
reported the preparation of liposomes, but also other structures to improve the targeting
ability of anticancer drugs.
In particular, supramolecular vesicular aggregates (SVAs) have been prepared via
the self-assembly of liposomes and FA-conjugated polyasparthydrazide co-polymers that
encapsulated GEM. The SVAs were then characterized [129]. The authors previously
demonstrated that SVAs do not alter the structure of the vesicles, allowing the systems to
deliver the entrapped drug efficiently. In vivo experiments in mice bearing MCF-7 human
xenografts, used as a breast-cancer model, showed that FA-decorated SVAs were more
active than GEM, whether they were free or loaded into liposomes.
Another research group has compared the cytotoxicity and selectivity of DOX-containing
liposomes and DOX that was conjugated to pullulan-based polymeric nanocarriers, both
with or without FA [130]. The FA-decorated liposomes were prepared via the post insertion
of the FA-DSPE (1,2-distearoyl-sn-glycero-3-phosphorylethanolamine) conjugate on the
Caelyx surface. The targeting ability of FA-containing DDS was demonstrated in vitro. The
in vivo experiments in FR-overexpressing human cervical carcinoma KB tumor-bearing
mice showed that both systems were active and able to reduce DOX-induced cardiotoxicity.
This work compared two receptor-targeted ligand-bearing systems, polymer therapeutics
versus nanoparticulate systems, and evaluated them in the same mouse tumor model at
several dosing regimens.
FA-decorated liposomes that contained a synthetic DOX that was conjugated with
a nitric oxide (NO)-releasing group, which have demonstrated the ability to overcome
resistance by inducing the NO-mediated inhibition of P-glycoprotein (Pgp), were prepared
and characterized. FA-liposomes were prepared using two different methods: FA-DSPE
conjugate insertion on liposomes via hydration (FA on both faces of the bilayer) and using
the post-insertion method (FA only on the external face of the bilayer). The formulations
were compared in terms of their technological features and in vitro behavior. The results
showed that FA-liposomes are internalized in a FR-dependent manner and achieve maxi-
mal antitumor efficacy against FR+/Pgp positive cells. In vivo experiments showed that
liposomes reduced the growth of FR+/Pgp-positive tumors and prevented tumor forma-
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tion in mice, whereas DOX and Caelyx failed. FA-liposome cardiotoxicity was comparable
to that of Caelyx [131].
Etoposide has been encapsulated into liposomes that were functionalized with anti-
GD2 mAb 3F8, which has demonstrated the ability to display anti-tumor effects via
antibody-directed cellular cytotoxicity and complement-mediated cytotoxicity [132]. GD2
is a disialated ganglioside that is expressed on tumors of neuroendocrine origin (melanoma,
osteosarcoma and neuroblastoma) [133]. Thiolated Ab was conjugated via a reaction with
DSPE-PEG-maleimide that was post inserted into the external surface of the liposomes. The
liposomes were fully characterized, and in vitro studies showed that immunoliposomes
entered the targeted cells via clathrin-dependent uptake, and a correlation between cellular
GD2 levels and the ability to target cells using etoposide-containing immunoliposomes
was observed [134].
Immunoliposomes that encapsulated 5-FU and were decorated with an Ab against the
Frizzled 10 (FZD10) protein, which is a cell surface receptor belonging to the FZD-protein
family and is overexpressed in colorectal cancer cells, were prepared and characterized.
The primary amine groups of the Ab were conjugated to liposomes that bore carboxylic
groups via crosslinking chemistry. In vitro studies showed that the cytotoxic activity of
immunoliposomes was enhanced compared to the free drug and untargeted liposomes,
indicating that the use of FZD10 protein as a novel, effective target for colorectal cancer
should be explored [135].
PEGylated lipoplexes that were either plain or conjugated to a mAb directed towards
primary effusion lymphoma cells and that contained a model oligonucleotide have been
prepared and characterized. The in vitro transfection efficiency was evaluated on BCBL-1
cells, and the mAb-containing lipoplexes displayed a significant increase in the transfection
rate and the localized internalization of the oligonucleotide, with respect to the plain
analogues [136]. The same group developed combined approaches, transmission electron
and atomic force microscopic techniques, to evaluate and identify the modification on the
surface of liposomes deeply [137].
Niosomes that were functionalized with the glucose-derivative N-palmitoylglucosamine
were developed as a potential brain-targeted delivery system [138]. Vesicles were loaded
with DOX and fully characterized in terms of size, surface charge and morphology. Pre-
liminary in vivo studies, performed on rats, showed that the glucose-targeted vesicles
significantly reduced the heart accumulation of the drug, prolonged its blood circula-
tion and were able to improve its brain delivery significantly, with respect to free DOX.
The exact mechanism of transport is not completely known, but the author indicated
some hypotheses.
A novel synthetic non-peptide oligo-arginine cell-penetration enhancer (CPE), formed
of four arginine units conjugated to a 2,2-bis(hydroxymethyl)-propionic acid (bis-MPA)/2,2-
bis(aminomethyl)propionic acid (bis-AMPA) polyester dendron that terminated in 1,2-
distearoyl-3-azidopropane (DAG-Arg4), has been proposed for liposome bilayer insertion.
Thanks to its dendritic structure, DAG-Arg4 has shown higher charge density and increased
cellular uptake than linear polypeptides and has a hydrophobic residue that anchors it to
the liposome bilayer [139]. Liposomes that encapsulated DOX and were decorated with
DAG-Arg4 have been tested in mice with an orthotropic model of breast cancer (4T1-Luc
murine mammary carcinoma), using several analytical approaches. DAG-Arg4-decorated
liposomes showed reduced tumor and spleen accumulation, similar liver accumulation and
higher lung accumulation than plain liposomes. However, their in vivo anticancer activity
was the highest and was probably due to the intra-tumoral permeability that is mediated by
the CPE on the liposome surface [140], which has been proposed as a targeting ligand for
hepatocellular carcinoma delivery [141]. The thyroid hormone triiodothyronine (T3), which
has a demonstrated role in hepatocellular carcinoma suppression, was encapsulated in
plain and Lf-decorated liposomes. Lf was thiolated and further conjugated onto the surface
of the preformed liposomes, which contained the DSPE-PEG-maleimide lipid. In vitro
studies on target cells (FaO, HepG2 and SKHep) showed that Lf-liposomes had higher cell
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binding and cellular uptake, with high affinity to multiple receptors on the cell surface,
than the non-decorated analogues. Cell-viability tests, performed using hepatoma cell
lines, demonstrated that all of the formulations had very low toxicity, but indicated that
liposomes may ensure specific and sustained drug delivery and a reduced therapeutic
dose, thus avoiding the side effects that are associated to T3 treatment [142].
Nanoliposomes that were decorated with a thyroid-stimulating hormone (TSH) were
prepared in order to target specifically the TSH receptor (TSHr), which is a glycoprotein
expressed in the plasma membranes of thyrocytes, and is maintained in most thyroid
pathologies and also present in the majority of less differentiated and more aggressive
tumors [143]. Decorated vesicles were prepared by conjugating the cysteine residue in
TSH with a thiol-activated moiety that is present on the surface of the nanoliposomes,
forming a disulfide bond. The nanoliposomes were fully characterized and showed an
increased uptake in cells with TSHr, in comparison with plain ones, as well as higher levels
of accumulation in normal thyroid tissue and in subcutaneous thyroid tumors. Finally,
GEM-loaded TSH-nanoliposomes displayed a significant improvement in in vitro and
in vivo anticancer activity [144].
Solid Lipid Nanoparticles (SLNs) are solid nanosystems based on lipid matrices
that are solid at body temperature, such as triglycerides, fatty acids, phospholipids and
waxes [145]. Thanks to several formulation strategies, it is possible to incorporate both
lipophilic and hydrophilic drugs and to scale-up production methods [146,147]. As SLNs
have demonstrated biocompatibility and the capability to improve drug bioavailability
by increasing their diffusion through biological membranes in several studies [148], the
development of actively tumor-targeted SLN formulations is currently in progress [149].
In the Italian landscape, SLNs have been proposed as nanosystems that are actively
targeted towards brain tumors. Endogenous and chimeric ligands have been directly or
indirectly bound to drug-loaded nanocarriers to obtain systems that can recognize brain
capillary endothelial cells and cerebral tumoral cells, making them a promising strategy in
oncology. Some researchers have studied SLNs as possible active targeting carriers for the
treatment of glioblastoma multiforme, and have selected MTX as a cytotoxic drug against
rat F98 glioma cells and prepared the lipophilic derivative di-dodecyl-MTX (ddMTX) to
be loaded into SLNs [150]. ddMTX-loaded behenic acid-SLNs were prepared using the
coacervation method, and active targeting was obtained using apolipoprotein E (ApoE), a
chimera peptide that can bind the very low-density lipoprotein (VLDL) receptor and anchor
to lipid surfaces via simple electrostatic interactions. ddMTX-loaded SLNs were shown
to have antiproliferative activity that is mediated by the induction of apoptotic death in
F98 glioma cells. Biodistribution studies in healthy rats demonstrated the superiority of
the ApoE-conjugated formulation. No difference was observed in brain uptake between
healthy rats and glioma models, and this is probably because the particle size exceeds the
fenestrations of glioma-altered BBB. On the other hand, differences in tumor growth rate
(measured through MRI) and apoptosis were observed in the control and treated rats.
With the aim of improving the data obtained in the work described above, stearic
acid and behenic acid-SLNs were loaded with ddMTX and surface-functionalized with
two different proteins, Tfr and INS, whose receptors are overexpressed on the BBB [151].
The surface-functionalization was obtained via the addition of a lipophilic (ST-MBS) or
PEGylated (ST-PEG-MBS) N-octadecil-3-maleimido-benzamide linker, which was added
to the fatty-acid micellar solution prior to acidification, while the proteins were thiolated
and grafted onto the exposed maleimide moiety on SLN surfaces. Both linkers made it
possible to graft proteins onto SLN surfaces, although ST-MBS allowed a higher protein
amount to be bound. In vitro permeation through hCMEC/D3 cells showed significantly
increased permeation through the hCMEC/D3 cells’ monolayer, compared to free MTX,
for both non-functionalized and functionalized SLNs. Only SLNs that were functionalized
with ST-PEG-MBS showed a significant increase in accumulation in the brain in an in vivo
study, although a higher protein amount was grafted with ST-MBS. Furthermore, capillary
depletion showed no endothelial-cell internalization for ST-MBS-grafted SLNs, and good
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uptake for ST-PEG-MBS-grafted SLNs. The authors highlighted the importance of a PEG
spacer between the SLN surface and the targeting protein for interactions with the receptor.
Squalene Nanoparticles. The “squalenoylation” approach allows drugs to be con-
jugated to natural and biocompatible SQ to produce tailored derivatives that are able to
self-assemble in water. The formed SQ nanoassemblies are multifunctional NPs with high
drug loading that, in most cases, display an improved pharmaceutical profile compared
to the parent compound [152]. In a paper on this topic, the anticancer agent GEM was
conjugated to 1,1′,2- trisnorsqualenic acid via the acylation of the C-4 nitrogen atom of
the cytosine nucleus. The hexapeptide CKAAKN was conjugated to SQ and then associ-
ated to GEM-SQ by co-nanoprecipitation to target GEM-SQ actively towards pancreatic
cancer cells. The obtained targeted NPs have demonstrated that they are not only able to
interact specifically with both cancer cells and angiogenic vessels, but also to favor the
normalization of the vasculature. Moreover, in vivo tests in RIP-Tag2 mice showed that
there was a higher reduction in tumor volume for CKAAKN-targeted SQ NPs than for
both the free drug and untargeted nanocarriers [153]. Since the strategy for coupling the
ligand to the NPs is of paramount importance, a study was performed to evaluate the
impact of the conjugation strategy on the in vitro targeting ability of peptide-decorated
GEM-SQ NPs. In more detail: In one approach, the CKAAKN peptide was first reacted
with a SQ derivative and then co-nanoprecipitated with GEM-SQ; in a second approach,
the peptide was conjugated to the surface of preformed GEM-SQ NPs. A higher binding
ability and better specific avidity towards the peptide receptor were displayed by NPs that
were prepared via the co-nanoprecipitation of the two SQ derivatives [154].
Most ligand classes and the strategies used to target the described polymer- and
lipid-based nanocarriers actively are summarized in Table 1, together with their specific
receptors and cancer types.
In Figures 2 and 3, SEM/TEM/AFM images of different NP typologies described in
the present paper are reported.
Table 1. Ligand-based actively tumor-targeted nanocarriers for the receptor-directed drug-targeting of various types of
cancer over the last 10 years of Italian research.
Ligand Nanosystem ConjugationStrategy Drug/Payload Receptor Cancer Type Ref.
Small molecules
FA Polymeric NPs(CHIT) amide bond MTX FR
cervical
adenocarcinoma [52]















biotin Micelles ester bond niclosamide biotin receptor lung carcinoma [68]





TSPO ligands Polymeric NPs(PLGA) ester bond 5-FU TSPO glioma [75]
TSPO ligands G(4)-PAMAMdendrimers amide bond
fluorescent probe
(fluorescein) TSPO glioma [76]
lactobionic acid G(4)-PAMAMdendrimers amide bond sorafenib
asialoglycoprotein
receptor liver cancer [77]
alendronate Polymeric NPs(PLGA) amide bond DOX bone hydroxyapatite bone cancer [78]





GEM FR breast cancer [129]
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FR breast cancer [131]
Peptides and
proteins
GNQWFI peptide Polymeric NPs(PCL) amide bond DTX VEGFR1
breast
adenocarcinoma [70]
GE11 peptide Polymeric NPs(PLGA) amide bond CUR EGFR
colon
adenocarcinoma [73]




































with the other lipids




with the other lipids
























ZOL TfR glioblastoma [124,125]





DOX TfR breast cancer [127]




DOX and CURC or DOX
and quercetin TfR breast cancer [128]
CPE (Arg4-DAG) Liposomes association to theliposome bilayer
model drugs (calcein or
BSA) cervical cancer [139]






T3 multiple receptors hepatocellularcarcinoma [142]
TSH Nanoliposomes covalent bond GEM TSHR thyroid carcinoma [144]
ApoE SLNs electrostaticinteraction MTX derivative VLDL
glioblastoma
multiforme [150]
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Table 1. Cont.
Ligand Nanosystem ConjugationStrategy Drug/Payload Receptor Cancer Type Ref.
Tf/INS SLNs covalent bond MTX derivative TfR/HIR glioblastomamultiforme [151]
CKAAKN peptide SQ NPs thioether bond GEM frizzled receptors pancreatic cancer [153]
CKAAKN peptide SQ NPs thioether bond GEM frizzled receptors pancreatic cancer [154]
Antibodies











(CHIT) reductive amination plasmid coding for HER2
murine DC marker

























5-FU anti-Frizzled 10protein (FZD10) colorectal cancer [135]
Hyaluronic acid





HA (LMW) Micelle-likealbumin NPs amide bond DOX CD44
breast
adenocarcinoma [61]
HA (HMW) Polymeric NPs(PLGA) physical adsorption sclareol CD44 breast cancer [62]
HA (LMW) Polymeric NPs(PLGA)
layer-by-layer
deposition DTX CD44 lung cancer [63]
HA (LMW) Polymeric NPs(PLGA)
layer-by-layer
deposition 5-FU/plasmid pL3 CD44 colon cancer [64]






CD44 breast cancer andcervix cancer [65,66]










































plasmid DNA CD44 lung cancer [117]
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anti-Luc siRNA CD44 metastatic lungcancer [119]
Figure 2. TEM/SEM images of polymeric NPs, NBs, SLNs, SQ NPs. 1. TEM images of uncoated and coated CUR-PLGA NPs.
Scale bar = 200 nm. (A) Uncoated CUR-PLGA NPs, (B) 1% CHIT-CUR-PLGA NPs, (C) wheat germ agglutinin-CUR-PLGA
NPs and (D) GE11-CUR-PLGA NPs [73]. Permitted reproduction under the terms and conditions of the Creative Commons
Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/, accessed on 15 May 2021). 2. (a) SEM image of
mAbHLA-G/MTX/PLGA NBs; (b) TEM image of mAbHLA-G/MTX/PLGA NBs. Scale bar = 100 nm. Image adapted with
permission [85]. Copyright Elsevier 2014. 3. SEM image of bevacizumab-loaded SLNs. Scale bar = 2 µm. Image reproduced
with permission from [155]. Permitted reproduction under the terms and conditions of the Creative Commons Attribution
(CC BY) license (https://creativecommons.org/licenses/by/4.0/, accessed on 15 May 2021) 4. Cryogenic TEM image of
GEM-SQ/CKAAKN-SQ NPs. Scale bar = 100 nm. Reproduced with permission from [153]. Copyright Elsevier 2014.
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1 
 
 Figure 3. AFM/TEM images of liposomes, niosomes and lipoplexes. 1. AFM images of different liposomes. “Height
images” (1) and “phase images” (2) of cationic liposomes (a), classic pegylated liposomes (b) and immunoliposomes (c).
Magnification of phase images; arrows indicate the detailed on liposomal surface. Image adapted with permission [137].
Copyright Taylor & Francis 2015. 2. Representative cryo-TEM images of Span20 niosomes coated with pH (low) insertion
peptide. Scale bar = 200 nm [101]. Permitted reproduction under the terms and conditions of the Creative Commons
Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/, accessed on 15 May 2021) 3. Cryo-TEM
images of (A) HA-liposomes, (B) HA-lipoplexes. Scale bar = 200 nm. Reproduced with permission from [120]. Copyright
American Chemical Society, 2015.
4. Conclusions
Many Italian researchers, including chemists, engineers and physicists, have been
working for years on the development of new nanotechnology-based DDS, and especially
on the synthesis of innovative materials and the development of new linking strategies
that can overcome the limitations of conventional anticancer therapies. Without wishing to
devalue these crucial contributions, this review focuses on research activity carried out,
since 2010, in Italian academic Pharmaceutical Technology laboratories on actively targeted
NPs for cancer management. Indeed, the recent Italian research panorama on actively
targeted NPs for cancer therapy has expanded significantly, generating promising results
in vitro and in vivo, and this is also thanks to the continuous drive to develop fruitful
multidisciplinary collaborations with national and international research groups.
Taking together the reported studies, we have observed constant evolution in the
development of ligands, with a progressive shift from small molecules to macromolecules.
Furthermore, ever-growing attention is being paid to optimizing the number of target-
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ing agent molecules and/or ligand exposure on the nanocarrier surface using various
decoration strategies.
In terms of nanocarrier types, liposomes are a consolidated approach as various surface
functionalization strategies have been adopted with different targeting ligands, including
FA, peptides and Ab. Many anticancer agents have been loaded into the developed
liposomes and successfully tested for their efficacy both in vitro and in vivo. As some
PEGylated liposomal formulations of DOX are already commercially available, it cannot
be excluded that the intelligent design of some actively targeted liposomes, in terms of
improving their selectivity towards tumor cells and the tumor microenvironment, might
hasten their clinical translation.
Actively targeted polymer-based nanocarriers are a highly heterogeneous group of
structures that have been developed starting from the accurate design of polymer synthesis
and functionalization in order to tune matrix characteristics precisely. Moreover, a great
variety of traditional and novel preparation methods has been proposed. The strategies
adopted to furnish these nanocarriers with tumor targeting mainly exploit FA decoration,
by optimizing the vitamin’s surface exposition, and the use of HA-decorated polymers.
Finally, the development of actively targeted SQ-NPs, SLNs and NBs in cancer therapy
is an interesting “niche” research field for some Italian groups, and one that seems to be
destined to improve the high physiological compatibility of these nanocarriers constantly
and the preliminary in vitro and in vivo results.
In conclusion, it is to be expected that ongoing research developments and future
perspectives will further optimize the safety, effectiveness and selectivity of the described
actively targeted nanocarriers for the future translation of this approach to the clinic.
Nevertheless, it must be underlined that, to achieve efficient clinical translation and to
allow an actively targeted nanocarrier to reach patient beds, additional multidisciplinary
research and established collaborations between academia, industry and regulatory bodies
will be required.
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EPR enhanced permeability and retention
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FR folate receptor
5-FU 5-fluorouracil
FZD10 frizzled 10 protein
GEM gemcitabine
HA hyaluronic acid













PLGA poly lactic-co-glycolic acid
PLA poly lactic acid
PSMA prostate-specific membrane antigen
PTX paclitaxel
SLN(s) solid lipid nanoparticle(s)
SQ squalene
SVA(s) supramolecular vesicular aggregate(s)
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